Resultados de la búsqueda 241-250 of 11696 for Lymphocytosis

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  5. Bispecific antibody therapy

    Bispecific antibody therapy uses medicines that target diseases in two ways at the same time. It uses specially designed, lab-made proteins called bispecific ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may ...

  7. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic ...

  8. Hematología - Ensayos clínicos - Mayo Clinic

    Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.